HUP0104439A3 - Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof - Google Patents

Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Info

Publication number: HUP0104439A3
Authority: HU; Hungary
Prior art keywords: corticosteroids; pharmaceutical compositions; modulating responsiveness; responsiveness; modulating
Prior art date: 1997-03-18

Application number

HU0104439A

Other languages

Hungarian (hu)

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-18

Filing date

1998-03-12

Publication date

2002-08-28

1997-03-18 Priority claimed from US08/820,692 external-priority patent/US6054487A/en

1998-03-12 Application filed by Basf Ag filed Critical Basf Ag

2002-04-29 Publication of HUP0104439A2 publication Critical patent/HUP0104439A2/en

2002-08-28 Publication of HUP0104439A3 publication Critical patent/HUP0104439A3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Transplantation (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU0104439A 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof HUP0104439A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/820,692 US6054487A (en)	1997-03-18	1997-03-18	Methods and compositions for modulating responsiveness to corticosteroids
US1634698A	1998-01-30	1998-01-30
PCT/US1998/004916 WO1998041232A2 (en)	1997-03-18	1998-03-12	Compositions for modulating responsiveness to corticosteroids

Publications (2)

Publication Number	Publication Date
HUP0104439A2 HUP0104439A2 (en)	2002-04-29
HUP0104439A3 true HUP0104439A3 (en)	2002-08-28

Family

ID=26688484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0104439A HUP0104439A3 (en)	1997-03-18	1998-03-12	Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Country Status (20)

Country	Link
EP (1)	EP0998300A1 (en)
JP (1)	JP2002504091A (en)
KR (1)	KR20000076420A (en)
CN (1)	CN1269722A (en)
AU (1)	AU734756B2 (en)
BG (1)	BG103808A (en)
BR (1)	BR9810409A (en)
CA (1)	CA2282845A1 (en)
DE (1)	DE998300T1 (en)
ES (1)	ES2146192T1 (en)
HU (1)	HUP0104439A3 (en)
ID (1)	ID22975A (en)
IL (1)	IL131815A0 (en)
NO (1)	NO994506L (en)
NZ (1)	NZ337769A (en)
PL (1)	PL336464A1 (en)
SI (1)	SI20110A (en)
SK (1)	SK122199A3 (en)
TR (1)	TR199902615T2 (en)
WO (1)	WO1998041232A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6706264B1 (en)	1994-03-14	2004-03-16	Genetics Institute, Llc	Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) *	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7220717B2 (en)	1997-08-14	2007-05-22	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
US7704944B2 (en)	1997-08-14	2010-04-27	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en)	1997-10-10	2001-02-06	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) *	1997-10-17	2001-05-30	Smithkline Beecham Corp	USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
ATE274920T1 (en) *	1997-10-31	2004-09-15	Wyeth Corp	USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANT REJECTION
EP1516630A3 (en) *	1997-10-31	2006-05-03	Wyeth	Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) *	1997-11-19	1999-05-27	Tanox Pharma B.V.	Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
DE69925268T2 (en) *	1998-03-16	2006-03-23	Cytovia, Inc., San Diego	Dipeptide caspase inhibitors and their use
CA2355345A1 (en) *	1998-11-27	2001-06-28	Technion Research & Development Foundation Ltd.	Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
DE69927520T2 (en) *	1998-12-09	2006-06-22	Protein Design Labs, Inc., Fremont	USE OF IL-12 ANTIBODIES FOR THE TREATMENT OF PSORIASIS
KR20010110667A (en)	1999-03-16	2001-12-13	추후보정	Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US7883704B2 (en)	1999-03-25	2011-02-08	Abbott Gmbh & Co. Kg	Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
DE19915465A1 (en) *	1999-04-06	2000-10-19	Apotech Res & Dev Ltd	Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
AU4213500A (en)	1999-04-09	2000-11-14	Cytovia, Inc.	Caspase inhibitors and the use thereof
IL131047A0 (en) *	1999-07-22	2001-01-28	Yeda Res & Dev	Use of il-18 inhibitors
WO2001016093A1 (en)	1999-08-27	2001-03-08	Cytovia, Inc.	SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
WO2001019373A2 (en) *	1999-09-17	2001-03-22	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en)	1999-10-12	2003-05-20	Cytovia, Inc.	Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
IL151044A0 (en)	2000-02-10	2003-04-10	Abbott Lab	Antibodies that bind human interleukin-18 and methods of making and using
ES2267778T3 (en) *	2000-06-06	2007-03-16	Glaxo Group Limited	COMPOSITION FOR THE TREATMENT OF CANCER, CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR.
WO2001097815A2 (en) *	2000-06-22	2001-12-27	Willy Ben Moussa Ben Mohammed	Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) *	2000-07-20	2002-02-28	Schering Ag	Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) *	2000-09-13	2002-03-21	Isis Innovation Limited	Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) *	2000-09-15	2002-04-24	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) *	2000-09-15	2002-03-20	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
SI1355668T1 (en) *	2001-01-29	2008-06-30	Serono Lab	Use of il-18 inhibitors for the treatment and/or prevention of heart disease
JP4502580B2 (en) *	2001-05-16	2010-07-14	イエダリサーチアンドディベロップメントカンパニーリミテッド	Use of IL-18 inhibitors for the treatment or prevention of sepsis
CN103232539B (en)	2001-06-26	2015-06-03	安姆根弗里蒙特公司	Antibodies to opgl
KR100824491B1 (en) *	2001-10-05	2008-04-22	콤비네이토릭스, 인코포레이티드	Combination for the treatment of immunoinflammatory diseases
JP2003342196A (en) *	2002-05-31	2003-12-03	Mukku:Kk	Composition for intravenous injection, method of production for the same and its preparation
BR0314713A (en) *	2002-09-24	2005-07-26	Combinatorx Inc	Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
WO2004028545A1 (en) *	2002-09-25	2004-04-08	Astrazeneca Ab	A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) *	2003-01-27	2006-04-20	Warner James M	Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
EP1752159A4 (en) *	2004-05-17	2009-07-01	Univ Keio	MEDICINAL COMPOSITION AND THERAPEUTIC METHOD
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
JP5595632B2 (en)	2004-07-16	2014-09-24	敦生関山	IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist
EP1810692A1 (en) *	2004-10-13	2007-07-25	Kyowa Hakko Kogyo Co., Ltd.	Remedies/preventives for chronic skin disease
US7829554B2 (en)	2005-07-14	2010-11-09	Lithera, Inc.	Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
WO2008048770A1 (en) *	2006-10-17	2008-04-24	Lipothera, Inc.	Methods, compositions, and formulations for the treatment of thyroid eye disease
SG177982A1 (en)	2007-01-16	2012-02-28	Abbott Lab	Methods for treating psoriasis
AU2008233173B2 (en)	2007-03-29	2013-09-19	Abbvie Inc.	Crystalline anti-human IL-12 antibodies
BRPI0908715A2 (en)	2008-03-18	2016-05-03	Abbott Lab	Methods for psoriasis treatment
US9132084B2 (en)	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
US9597531B2 (en)	2010-11-24	2017-03-21	Neothetics, Inc.	Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en)	2013-10-30	2015-05-07	Wockhardt Limited	Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
US12102622B2 (en)	2021-02-10	2024-10-01	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
IL311534A (en)	2021-09-22	2024-05-01	Iolyx Therapeutics Inc	Methods for treating ocular inflammatory diseases
WO2024215900A2 (en) *	2023-04-12	2024-10-17	The Board Of Trustees Of The University Of Illinois	Agonists of small heterodimer partner for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3320125A (en) *	1964-04-28	1967-05-16	Merck & Co Inc	Inhalation aerosol composition
NZ235222A (en) *	1989-09-08	1992-11-25	Glaxo Group Ltd	Inhalatory composition comprising salmeterol and beclomethasone dipropionate
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) *	1992-02-06	1992-03-25	Glaxo Group Ltd	Medicaments
MX9304585A (en) *	1992-07-31	1994-03-31	Glaxo Group Ltd	PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) *	1994-12-24	1995-02-22	Glaxo Group Ltd	Pharmaceutical composition
EP0820414B1 (en) *	1995-04-14	2004-02-04	SmithKline Beecham Corporation	Metered dose inhaler for beclomethasone dipropionate

1998
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/en unknown
- 1998-03-12 CN CN98805124A patent/CN1269722A/en active Pending
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/en not_active IP Right Cessation
- 1998-03-12 NZ NZ337769A patent/NZ337769A/en unknown
- 1998-03-12 IL IL13181598A patent/IL131815A0/en unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/en active Pending
- 1998-03-12 DE DE0998300T patent/DE998300T1/en active Pending
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 ID IDW991185A patent/ID22975A/en unknown
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 JP JP54063398A patent/JP2002504091A/en active Pending
- 1998-03-12 PL PL98336464A patent/PL336464A1/en unknown
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/en unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/en not_active Withdrawn
- 1998-03-12 SI SI9820032A patent/SI20110A/en unknown
- 1998-03-12 SK SK1221-99A patent/SK122199A3/en unknown
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Ceased
1999
- 1999-09-17 NO NO994506A patent/NO994506L/en unknown
- 1999-10-13 BG BG103808A patent/BG103808A/en unknown

Also Published As

Publication number	Publication date
BG103808A (en)	2000-07-31
PL336464A1 (en)	2000-06-19
WO1998041232A3 (en)	2000-10-05
ID22975A (en)	1999-12-23
NZ337769A (en)	2002-09-27
SK122199A3 (en)	2000-12-11
ES2146192T1 (en)	2000-08-01
BR9810409A (en)	2000-08-22
IL131815A0 (en)	2001-03-19
DE998300T1 (en)	2001-03-01
SI20110A (en)	2000-06-30
HUP0104439A2 (en)	2002-04-29
KR20000076420A (en)	2000-12-26
CA2282845A1 (en)	1998-09-24
AU6760498A (en)	1998-10-12
NO994506D0 (en)	1999-09-17
AU734756B2 (en)	2001-06-21
JP2002504091A (en)	2002-02-05
CN1269722A (en)	2000-10-11
WO1998041232A2 (en)	1998-09-24
EP0998300A1 (en)	2000-05-10
NO994506L (en)	1999-11-17
TR199902615T2 (en)	2000-03-21

Publication	Publication Date	Title
HUP0104439A3 (en)	2002-08-28	Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
PL322494A1 (en)	1998-02-02	Compounds and compositions intended to provide active substances
HUP0003761A3 (en)	2001-04-28	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0101999A3 (en)	2003-06-30	4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
IL114229A (en)	1999-05-09	Compositions for applying active substances to or through the skin
HUS1200028I1 (en)	2016-08-29	4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivatives and pharmaceutical compositions containing them
HUP9702035A3 (en)	1998-12-28	Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en)	1998-12-28	Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en)	1998-12-28	Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
IL131319A0 (en)	2001-01-28	3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same
HUP0001541A3 (en)	2001-11-28	Phthalazinone derivatives and pharmaceutical compositions containing them
PL330880A1 (en)	1999-06-07	Liquid antiperspirant and deodorising composition
HUP0001309A3 (en)	2000-12-28	1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HUP9900424A2 (en)	1999-05-28	Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
IL136937A0 (en)	2001-06-14	τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL133097A0 (en)	2001-03-19	Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
HUP0002510A3 (en)	2002-10-28	Tetrazole derivatives and pharmaceutical compositions containing them
AU7127600A (en)	2001-04-17	Methods and compositions for modulating responsiveness to corticosteroids
HUP9901452A3 (en)	2001-02-28	Bicyclic-aromatic compounds and pharmaceutical compositions containing them
HUP9800147A3 (en)	1999-01-28	Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
PL330396A1 (en)	1999-06-21	Solid cosmetic composition and application thereof
HUP0100085A3 (en)	2002-12-28	Biphenylamidine derivatives and pharmaceutical compositions containing them
AP9600866A0 (en)	1996-10-31	Benzamine derivative compositions containing said derivative and use thereof
HUP0001858A3 (en)	2002-01-28	Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds
HUP0002331A3 (en)	2001-05-28	20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof